REG - Redx Pharma plc - Exercise of Options, PDMR Dealing and TVR

Redx PharmaAnnouncement

26/07/2022 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220726:nRSZ8023Ta&default-theme=true

RNS Number : 8023T  Redx Pharma plc  26 July 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Exercise of Options, PDMR Dealing and Total Voting Rights

 

Alderley Park, UK, 26 July 2022 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, announces the exercise of share options by current and
former employees of the Company over a total of 1,058,297 new ordinary shares
of 1 pence each in the capital of the Company ("Ordinary Shares") at exercise
prices ranging from 15.5 to 56 pence per share.

 

In addition, options over 500,000 new ordinary shares of 1 pence each in the
capital of the Company were exercised by Richard Armer (Chief Scientific
Officer) who is classed as a person discharging managerial responsibility
("PDMR") under EU Regulation 596/2014 as it forms part of domestic law in
the United Kingdom by virtue of the European Union (Withdrawal) Act 2018,
as set out further below.

 

 Name           Position                  Number of share options exercised  Exercise price  Total options held following exercise
 Richard Armer  Chief Scientific Officer  500,000                            15.5 pence      6,084,378

 

Application has been made to the London Stock Exchange for the 1,558,297 new
Ordinary Shares to be admitted to trading on AIM and admission is expected to
occur at or around 8.00 am on Wednesday 27(th) July 2022. The new Ordinary
Shares will rank pari passu with the existing Ordinary Shares in issue.

 

Total Voting Rights

 

For the purpose of the Disclosure Guidance and Transparency Rules, following
the above issue of equity, the issued share capital of the Company will
comprise 334,911,458 Ordinary Shares. The above figure may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the Company, under the Disclosure Guidance and Transparency
Rules.

 For further information, please contact:

 Redx Pharma Plc                                                      T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                          T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                       T: +44 (0)203 705 9330
 Claes Spång/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                           T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                       T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase
2 programme in November 2021. The Company's lead fibrosis product candidate,
the selective ROCK2 inhibitor RXC007, is in development for idiopathic
pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021.
Encouraging safety and pharmacokinetic data has been reported, and a Phase 2
clinical programme is confirmed to start in 2022. Redx's third drug candidate,
RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic
Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies
expected to commence in 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor
targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF),
which AstraZeneca is progressing in a Phase 1 clinical study. In addition,
Redx has forged collaborations with Jazz Pharmaceuticals, which includes
JZP815, a preclinical pan-RAF inhibitor, which has received IND approval and a
further oncology programme which is in early stage research.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
(http://www.redxpharma.com/investor-centre/email-alerts/)

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)   Name                                    Richard Armer
 2.  Reason for the notification
 a)  Position/status                          Chief Scientific Officer
 b)  Initial notification/Amendment           Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     Redx Pharma Plc
 b)  LEI                                      213800HMS4EBXO589Y37
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 1p each
 b)  Identification code                      ISIN: GB00BSNB6S51
 c)  Nature of the transactions               Exercise of options under the Redx Share Option Scheme
 d)  Price(s) and volume(s)                   Exercise Price: 15.5p per share

                                              Volume: 500,000
 e)  Aggregated information                   As for d) above

     -     Aggregated volume

     -     Price
 f)  Date of the transactions                 26 July 2022
 f)  Place of the transactions                Off-market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBDGDRLSDDGDL